Search Result for:
Treatments Differ Across Centers in Systemic JIA
Significant variations were seen across hospitals in the treatment of children admitted with new-onset…
View Resource
Canakinumab Tapering in Still's Disease
You can reduce – but not stop – canakinumab therapy in patients who are…
View Resource
Canakinumab First FDA-Approved Therapy for Adult-Onset Still's Disease
Yesterday, the FDA approved canakinumab (Ilaris) as treatment for adult-onset Still’s disease (AOSD), the…
View Resource
TNR Grand Rounds – Cytokine Storm Syndromes
This week’s Tuesday Nite Rheumatology featured Dr Randy Cron from the University of Alabama –…
View Resource
Earlier Anakinra Initiation Warranted in Still's Disease
An Italian study examined the outcomes in adult onset Still’s disease (AOSD) based on…
View Resource
Tofacitinib Effective in Refractory Still's Disease
Fourteen cases reported from mainland China suggest that tofacitinib (TOFA) may be effective in…
View Resource
Cytokine Inhibitor Lung Disease in Still's Linked to HLA-DRB1 Alleles
Pulmonary complications in the setting of Still’s disease (both juvenile and adult) has seldom…
View Resource